Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline

PARIS, FRANCE, 21 AUGUST 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III clinical development in myelofibrosis. About navtemadlinNavtemadlin is an investigational oral MDM2 inhibitor being developed as an add-on therapy to…

financialpost.com ·2h ago

We haven't written up this one. Financial Post has the full story — the link below goes straight to it.

Read the original at financialpost.com →

Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline

More in Business

Back on track: can Burnham fix the north’s woeful rail services?

I’ll admit it: I’ve cycled through red lights. But Britain’s traffic laws are to blame, not me | Simon Jenkins

Germans could save over €12,000 by ditching gas boiler for solar, battery and heat pump – analysis

Hindustan Zinc shares jump 7% in two sessions. What’s triggering the rally?

WordroW of the day: Guess the hidden word

Chimica, il prezzo di Hormuz e concorrenza cinese è un 2026 ancora in negativo